OneSource Reaffirms FY28 $400M Guidance on DDC Invoicing

OneSource Specialty Pharma Limited — Q4 FY26 Earnings Call (Quarter & FY ended Mar 31, 2026) | Call held May 13, 2026

1. Overall Tone of Management: Optimistic

• Management highlights a “strong comeback” in Q4 and attributes it to operational milestones: “start invoicing our drug device combinations.”
• They emphasize regulatory momentum and readiness: “received approvals for Canada” and “a very strong compliance track record.”
• They reiterate confidence in forward growth: “reaffirm our long-term guidance of FY ’28… US$400 million… ~40% EBITDA margins.”

2. Key Themes from Management Commentary

• DDC/GLP-1 ramp-up after approvals
• Q4 recovery tied to invoicing and shipping post-approval; Canada approvals and “tentative approval” for US partner(s).
• “uptick on our quarterly performances” expected going forward.
• Capacity expansion on track to meet demand
• Second line “now… undergoing engineering and qualification trials,” expected availability in Q2.
• FY27 ramp framed as sequential improvements driven by new lines; by end-FY27 they expect three lines installed.
• Semaglutide commercial traction and market share
• India launch described as moving from “pipeline to real proof,” with partners present “on day one.”
• Claim: customer base holds “almost two-thirds of the Indian market share by value” (generic semaglutide).
• Biologics momentum (longer gestation)
• Biologics funnel described as “historic high,” expanded “almost 4x” YoY; multiple new partner/project additions.
• Management guides meaningful contribution in FY27/FY28, with commercial manufacturing “’29 onwards.”
• Compliance and regulatory execution as a core moat
• “49 regulatory and customer audits,” surprise FDA inspection with successful outcomes; renewed EU GMP and ANVISA approval.
• Governance / capital allocation narrative shift: scheme deferred
• Related-party/inorganic transaction (Steriscience/Brooks assets) deferred due to valuation concerns and to align with delivery of organic targets.

3. Q&A Analysis

Theme A: Brazil market access & tariff/local manufacturing risk

• Core question(s):
• How will Brazil’s local manufacturing duty (28%) be handled, and does it hinder growth?
• Management response:
• Duty applies only if local manufacturing exists; “as we speak, there is no manufacturing which is available in Brazil.”
• CDMO terms are “ex-works,” implying tariff impact is on customers.
• Assessment:
• Direct and specific; no clear mitigation beyond contractual/ex-works framing.

Theme B: Customer economics / profit-sharing & confidentiality

• Core question(s):
• Whether profit-sharing arrangements exist with other regulated-market customers similar to Natco+Mylan.
• Management response:
• “We neither do we talk about which customers we have or the terms” citing confidentiality.
• Assessment:
• Deflective/limited disclosure; answers the confidentiality boundary rather than the substance.

Theme C: Working capital / inventory build (why inventory surged)

• Core question(s):
• Inventory increased from INR158 cr (Mar’25) to INR440 cr (Mar’26). Is it risky? Does it flow through P&L?
• Management response:
• Inventory is “part of our entire production process,” “purchases are fully funded by our customers and fungible.”
• Inventory movements adjust against customer advances; “impact… on the P&L is practically negligible.”
• Assessment:
• Strong reassurance, but relies on accounting/contract mechanics; no quantified sensitivity provided.

Theme D: Opex/staff cost vs revenue scale; what revenue supports the spend

• Core question(s):
• Elevated H2 investments (staff/expenses) despite softer revenue—what revenue scale will they support? What EBITDA margins in non-CDMO injectable/capsule business?
• Management response:
• Working capital and opex are “as expected and as planned” for upcoming launches; inventories are customer-funded.
• Opex supports capacity expansion tied to FY28 $400m guidance; second line qualification drives opex now and revenue later.
• Non-CDMO margin question not directly answered with numbers; focus stayed on DDC expansion.
• Assessment:
• Partially evasive on segment margin quantification; more direct on DDC capacity linkage.

Theme E: Capacity timelines, utilization, and when biologics becomes meaningful

• Core question(s):
• When incremental capacity becomes available; utilization assumptions; when biologics contributes meaningfully to EBITDA; breakeven year.
• Management response:
• New line available “from next quarter onwards”; by end-FY27 three lines installed.
• Capacity described via “sterile days” and batch-size-dependent output; no utilization % given.
• Biologics: meaningful contribution FY27/FY28; “commercial manufacturing… ’29 onwards”; breakeven/profitability granularity refused due to confidentiality.
• Assessment:
• Utilization guidance is non-quantitative; biologics financial disclosure is withheld.

Theme F: Semaglutide volume commitments / take-or-pay mechanics

• Core question(s):
• Any minimum volume commitments irrespective of customer sell-through? Will terms change as more markets open?
• Management response:
• Customers reserve capacity with “blocking capacity” and “take-or-pay kind of contract” including upfront fees.
• Over next “2 years” demand-supply gap expected to remain supply-constrained.
• Assessment:
• Clear on capacity reservation; still avoids explicit volume numbers.

Theme G: Semaglutide Canada approvals for other clients

• Core question(s):
• Timing of approvals for other Canadian clients; whether FY27 or beyond.
• Management response:
• Not directly involved in regulatory strategy; expects more approvals “over the next few quarters.”
• Assessment:
• No firm timing; relies on public commentary from Health Canada.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY28 organic guidance reiterated:
• “US$400 million of organic revenue with around 40% of EBITDA margins.”
• Capex:
• “US$100 million capex” for the new line (line installed; qualification ongoing; availability next quarter).
• Capacity availability / ramp milestones (timing):
• Second line expected available Q2.
• “By end of the year, we will have three lines installed” (implying FY27 readiness).

Implicit signals (qualitative)

• Sequential improvement expected: “uptick on our quarterly performances going forward.”
• Demand visibility: “clear visibility on… robust demand” and “demand-supply gap… at least for next 2 years.”
• Biologics runway: meaningful FY28 contribution, but commercial manufacturing “beyond current time horizon… ’29 onwards.”
• FY27 numbers not re-guided: management says they will “stay right now with FY28 guidance” while progressing commercial launches.

5. Standout Statements (direct / revealing)

• Operational driver of recovery: “strong comeback… because we’ve been able to start invoicing our drug device combinations.”
• Regulatory momentum: “received approvals for Canada” and partner approvals include “tentative approval” for the US.
• Long-term anchor (reaffirmed): “US$400 million… with around 40% of EBITDA margins” for FY28.
• Capacity execution confidence: “capacity expansion remains very much on track” and second line “expect… available… in Q2.”
• Working capital defense: inventories are “fully funded by our customers and fungible” and “impact… on the P&L is practically negligible.”
• Inorganic deal deferred (governance + valuation):
• “we decided that it’s best that we defer this transaction… until such time both OneSource delivers on its US$400 million… and incoming assets deliver on its US$40 million of EBITDA.”
• Biologics disclosure boundary: management refuses to break down revenue/profitability “because… confidentiality of our customers.”

6. Red Flags / Positive Signals

Red flags
– Limited transparency on economics: profit-sharing and customer terms are repeatedly refused (confidentiality), limiting ability to model margins/earnings quality.
– No utilization % / no hard volume commitments: capacity is discussed, but utilization and revenue conversion are not quantified.
– Biologics financial disclosure withheld: no revenue/EBITDA loss or breakeven year specifics despite direct questions.
– Inventory surge explanation relies on accounting mechanics: “customer-funded/fungible” claims are plausible but not independently evidenced with numbers.

Positive signals
– Clear operational milestones achieved (Canada approvals; invoicing; shipping; GLP shipments).
– Compliance track record emphasized with specifics (FDA surprise inspection, EIRs, EU GMP renewals, ANVISA approval).
– Capacity expansion timeline appears concrete (Q2 availability; end-FY27 three lines).
– Demand-supply gap narrative supports sequential ramp credibility.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Q1 FY26 (Aug’25): cautious on H1 (“muted H1”), emphasized ambiguity and that revenue recognition may lag due to approvals.
• Q2 FY26 (Nov’25): still bullish but acknowledged uncertainty around semaglutide approvals; however, tone was “very bullish” and reiterated guidance.
• Q4 FY26 (May’26): more confident/optimistic:
• “strong comeback,” “start invoicing,” “received approvals for Canada,” and “uptick… going forward.”
• Classification: More Optimistic than prior calls, with fewer “ambiguity” caveats and more “approvals/shipments” evidence.

b. Tracking Past Commitments vs Outcomes

• Capacity readiness / schedule acceleration
• Past statement (Q2 FY26): capacity expansion accelerated; “fully ready by end of calendar year ’26” and “almost a year ahead” of prior schedule.
• Current call: second line available in Q2; three lines installed by end-FY27; implies progress is on track.
• Status: ✅ Likely delivered / on track (no explicit contradiction).
• FY28 guidance stability
• Past (Q1/Q2): reiterated $400m organic / 40% EBITDA as long-term anchor.
• Current: reiterated again; no downgrade.
• Status: ✅ Maintained.
• Inorganic transaction (Steriscience/Brooks)
• Past (Q1 FY26): promoters discussed bringing assets under OneSource umbrella; expected value accretive; early days.
• Current: transaction deferred due to valuation drop and to align with organic/incoming EBITDA delivery.
• Status: ⏳ Delayed / dropped from near-term (not executed as planned).

c. Narrative Shifts

• From “regulatory ambiguity” → “commercial proof”
• Earlier calls stressed uncertainty in revenue recognition and approval timing.
• Now management repeatedly cites approvals and invoicing/shipping as the reason for performance recovery.
• Inorganic growth story softened
• Earlier inorganic opportunities were framed as upside to FY28.
• Now it’s “on the back burner,” explicitly tied to hitting organic targets and incoming EBITDA.
• Biologics moved from “nascent” to “historic funnel high”
• Still long gestation, but the funnel expansion and partner additions are emphasized more concretely.

d. Consistency & Credibility Signals

• Credibility: Medium-High
• Strength: operational milestones (Canada approvals, invoicing, compliance outcomes) are tangible.
• Weakness: recurring refusal to quantify key items (biologics profitability/breakeven, customer profit-sharing, utilization) reduces verifiability.
• No major contradictions found in capacity timing, but inorganic deferral is a meaningful shift.

e. Evolution of Key Themes

• Demand (Semaglutide): Improving/stable—now framed as robust with “visibility” and “demand-supply gap.”
• Margins: Improving sequentially in Q4 (operating leverage on CSA revenues), but full-year EBITDA down due to delayed approvals—acknowledged.
• Compliance: Consistently highlighted as a differentiator; more specific regulatory events cited in Q4.
• Expansion execution: More concrete timelines in Q4 (Q2 availability, end-FY27 three lines).
• Biologics: Funnel growth narrative strengthened; profitability timing remains non-quantified.

f. Additional Insights (cross-period intelligence)

• Inventory/working capital narrative appears to have matured:
• Earlier calls warned about muted H1 and working capital build for long-lead items.
• In Q4, management gives a more explicit “customer-funded/fungible” defense for the inventory spike—suggesting investors’ concerns have persisted and management is proactively addressing them.
• Governance-driven capital allocation is tightening:
• Deferring the scheme due to valuation drop and shareholder comfort indicates management is willing to pause growth initiatives rather than force transactions—could be positive for governance, but also signals execution risk on inorganic upside.